Influenza vaccination in systemic lupus erythematosus: Safe and protective?

Autoimmunity Reviews

Volumn 6, Issue 5, 2007, Pages 300-305

  Holvast, Bert ^a   Huckriede, Anke ^a   Kallenberg, Cees G M ^a   Bijl, Marc ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Humoral and cell mediated immunity; Influenza vaccination; Systemic lupus erythematosus; Vaccine immunogenicity

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; PREDNISONE;

ANTIBODY RESPONSE; ANTIBODY TITER; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; LIVER TRANSPLANTATION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION; VIRUS INFECTION;

ANTIBODY FORMATION; HUMANS; IMMUNITY, CELLULAR; INFLUENZA VACCINES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, IMMUNOLOGICAL; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION;

EID: 33947715022     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.09.012     Document Type: Review

References (40)

1. Hayden F.G. Prevention and treatment of influenza in immunocompromised patients. Am J Med 102 3A (1997) 55-60
2. Fessler B.J. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol 16 2 (2002) 281-291
3. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 48 RR-4 (1999) 1-28
4. Aron-Maor A., and Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus 10 3 (2001) 237-240
5. Herron A., Dettleff G., Hixon B., Brandwin L., Ortbals D., Hornick R., et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA 242 1 (1979) 53-56
6. Louie J.S., Nies K.M., Shoji K.T., Fraback R.C., Abrass C., Border W., et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 88 6 (1978) 790-792
7. Abu-Shakra M., Press J., Sukenik S., and Buskila D. Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies. Clin Rheumatol 21 5 (2002) 369-372
8. Abu-Shakra M., Zalmanson S., Neumann L., Flusser D., Sukenik S., and Buskila D. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol 27 7 (2000) 1681-1685
9. Kanakoudi-Tsakalidou F., Trachana M., Pratsidou-Gertsi P., Tsitsami E., and Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol 19 5 (2001) 589-594
10. Ristow S.C., Douglas Jr. R.G., and Condemi J.J. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med 88 6 (1978) 786-789
11. Brodman R., Gilfillan R., Glass D., and Schur P.H. Influenzal vaccine response in systemic lupus erythematosus. Ann Intern Med 88 6 (1978) 735-740
12. Williams G.W., Steinberg A.D., Reinertsen J.L., Klassen L.W., Decker J.L., and Dolin R. Influenza immunization in systemic lupus eruthematosus. A double-blind trial. Ann Intern Med 88 6 (1978) 729-734
13. Holvast A., Huckriede A., Wilschut J., Horst G., De Vries J.J., Benne C.A., et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 65 7 (2006) 913-918
14. Del Porto F., Lagana B., Biselli R., Donatelli I., Campitelli L., Nisini R., et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 24 16 (2006) 3217-3223
15. Turner-Stokes L., Cambridge G., Corcoran T., Oxford J.S., and Snaith ML. In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases. Ann Rheum Dis 47 7 (1988) 532-535
16. Ioannou Y., and Isenberg D.A. Immunisation of patients with systemic lupus erythematosus: the current state of play. Lupus 8 7 (1999) 497-501
17. Wilschut J., and McElhaney J.E. Rapid reference influenza (2005), Mosby/Elsevier Science
18. McElhaney J.E. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 23 Suppl 1 (2005) S10-S25
19. Deng Y., Jing Y., Campbell A.E., and Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 172 6 (2004) 3437-3446
20. Brown D.M., Roman E., and Swain SL. CD4 T cell responses to influenza infection. Semin Immunol 16 3 (2004) 171-177
21. Doherty P.C., Topham D.J., Tripp R.A., Cardin R.D., Brooks J.W., and Stevenson P.G. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 159 (1997) 105-117
22. Gross P.A., Hermogenes A.W., Sacks H.S., Lau J., and Levandowski R.A. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 123 7 (1995) 518-527
23. de Jong J.C., Palache A.M., Beyer W.E., Rimmelzwaan G.F., Boon A.C., and Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115 (2003) 63-73
24. Gravenstein S., Drinka P., Duthie E.H., Miller B.A., Brown C.S., Hensley M., et al. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am Geriatr Soc 42 3 (1994) 245-251
25. Murasko D.M., Bernstein E.D., Gardner E.M., Gross P., Munk G., Dran S., et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 37 2-3 (2002) 427-439
26. Abu-Shakra M., Press J., Varsano N., Levy V., Mendelson E., Sukenik S., et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 29 12 (2002) 2555-2557
27. European Medicines Agency (EMEA). Note for guidance on harmonisation of requirements for influenza vaccines (1997) CPMP/BWP/214/96
28. Rimmelzwaan G.F., Nieuwkoop N., Brandenburg A., Sutter G., Beyer W.E., Maher D., et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 19 9-10 (2000) 1180-1187
29. Avery R.K. Vaccination of the immunosuppressed adult patient with rheumatologic disease. Rheum Dis Clin North Am 25 3 (1999) 567-584 viii
30. Bermas B.L., Petri M., Goldman D., Mittleman B., Miller M.W., Stocks N.I., et al. T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity. J Clin Immunol 14 3 (1994) 169-177
31. Grondal G., Gunnarsson I., Ronnelid J., Rogberg S., Klareskog L., and Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 18 5 (2000) 565-570
32. Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache A.M., et al. The virosome concept for influenza vaccines. Vaccine 23 Suppl 1 (2005) S26-S38
33. McElhaney J.E., Gravenstein S., Upshaw C.M., Hooton J.W., Krause P., Drinka P., et al. Granzyme B: a marker of risk for influenza in institutionalized older adults. Vaccine 19 27 (2001) 3744-3751
34. Gluck T. Vaccinate your immunocompromised patients!. Rheumatology (Oxford) 45 1 (2006) 9-10
35. Engelhard D., Nagler A., Hardan I., Morag A., Aker M., Baciu H., et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 11 1 (1993) 1-5
36. Kroon F.P., van Dissel J.T., de Jong J.C., and van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 8 4 (1994) 469-476
37. Soesman N.M., Rimmelzwaan G.F., Nieuwkoop N.J., Beyer W.E., Tilanus H.W., Kemmeren M.H., et al. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol 61 1 (2000) 85-93
38. Gluck R., Mischler R., Finkel B., Que J.U., Scarpa B., and Cryz Jr. S.J. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344 8916 (1994) 160-163
39. Conne P., Gauthey L., Vernet P., Althaus B., Que J.U., Finkel B., et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 15 15 (1997) 1675-1679
40. Bungener L., Huckriede A., de Mare A., Vries-Idema J., Wilschut J., and Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 23 10 (2005) 1232-1241